We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+16.87%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$493M
AUM Growth
+$4.13M
(+0.85%)
Cap. Flow
-$34.1M
Cap. Flow
% of AUM
-6.93%
Top 10 Holdings %
Top 10 Hldgs %
38.08%
Holding
111
New
22
Increased
19
Reduced
35
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$13.5M |
| 2 |
Cigna
CI
|
+$9.96M |
| 3 |
Merck
MRK
|
+$9.66M |
| 4 |
Icon
ICLR
|
+$9.38M |
| 5 |
GSK
GSK
|
+$9.35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$13.1M |
| 2 |
Cencora
COR
|
+$12.5M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
+$12.3M |
| 4 |
Sanofi
SNY
|
+$10.7M |
| 5 |
Amgen
AMGN
|
+$9.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.45% |
| 2 | Consumer Staples | 1.34% |
| 3 | Technology | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Teva Pharmaceuticals
TEVA
$40.5B
| $6.23M | 1.26% |
539,947
-150,439
| -22% | -$1.73M |
|
|
VAPO
27
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $6.2M | 1.26% |
32,283
+22,570
| +232% | +$5.24M |
|
28
Kura Oncology
KURA
$817M
| $6.04M | 1.23% |
213,471
+81,188
| +61% | +$2.57M |
|
|
HZNP
29
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.96M | 1.21% |
64,801
-34,100
| -34% | -$2.88M |
|
|
CCRN
30
DELISTED
Cross Country Healthcare
CCRN
| $5.41M | 1.1% |
433,244
-51,920
| -11% | -$550K |
|
|
AYLA
31
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| $5.35M | 1.09% |
489,988
+333,333
| +213% | +$4.76M |
|
|
ASLN
32
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $4.85M | 0.99% |
36,213
+1,397
| +4% | +$177K |
|
|
RDUS
33
DELISTED
Radius Health, Inc.
RDUS
| $4.82M | 0.98% |
230,957
-62,200
| -21% | -$1.31M |
|
34
Ardelyx
ARDX
$1.21B
| $4.77M | 0.97% |
720,621
+31,300
| +5% | +$215K |
|
35
Novavax
NVAX
$1.27B
| $4.66M | 0.95% |
+25,700
| New | +$5.12M |
|
36
Emergent Biosolutions
EBS
$389M
| $4.65M | 0.94% |
+50,000
| New | +$5.12M |
|
|
DCOY
37
Decoy Therapeutics
DCOY
$2.23M
| $4.62M | 0.94% |
87
+41
| +89% | +$2.35M |
|
|
SYNH
38
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $4.55M | 0.92% |
60,025
-4,975
| -8% | -$375K |
|
39
Vertex Pharmaceuticals
VRTX
$123B
| $4.53M | 0.92% |
21,067
-5,133
| -20% | -$1.13M |
|
|
NTUS
40
DELISTED
Natus Medical Inc
NTUS
| $4.34M | 0.88% |
169,454
-17,379
| -9% | -$446K |
|
|
AFMD
41
DELISTED
Affimed
AFMD
| $4.33M | 0.88% |
+54,804
| New | +$3.56M |
|
42
MacroGenics
MGNX
$248M
| $4.14M | 0.84% |
+130,000
| New | +$3.16M |
|
43
Moleculin Biotech
MBRX
$2.76M
| $3.93M | 0.8% |
+2,568
| New | +$4.71M |
|
|
CNST
44
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $3.89M | 0.79% |
166,186
+73,686
| +80% | +$2.23M |
|
45
Viking Therapeutics
VKTX
$3.91B
| $3.6M | 0.73% |
569,780
-40,000
| -7% | -$281K |
|
46
Cellectar Biosciences
CLRB
$20.1M
| $3.52M | 0.72% |
7,294
-476
| -6% | -$283K |
|
47
Precision BioSciences
DTIL
$193M
| $3.41M | 0.69% |
10,979
+391
| +4% | +$137K |
|
|
EFOR
48
Everforth Inc
EFOR
$1.3B
| $3.3M | 0.67% |
34,577
-28,500
| -45% | -$2.63M |
|
49
Syndax Pharmaceuticals
SNDX
$1.77B
| $3.27M | 0.66% |
146,142
-24,000
| -14% | -$542K |
|
50
Spyre Therapeutics
SYRE
$9.06B
| $3.19M | 0.65% |
16,106
+8,462
| +111% | +$1.62M |
|
Similar funds
GUB
KLI
JA
WIC
AAM
TCM
CA
SAM
Sio Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Sio Capital Management held 111 positions worth $493M, up 0.85% from $489M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Sio Capital Management withdrew a net $34.1M in Q1 2021, closing 22 positions and reducing 35 holdings. Its most notable exit was AstraZeneca, an estimated $13.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 82% a quarter earlier, followed by Consumer Staples and Technology.
Against the trend, Sio Capital Management opened a new position in Centene worth $13.9M.
- Sio Capital Management's largest Q1 2021 buy was Centene: 217,500 shares worth $13.9M.
- Sio Capital Management added most to Cigna in Q1 2021, an estimated $9.96M increase.
- Sio Capital Management's biggest Q1 2021 reduction was Curis, cutting an estimated $3.92M.
- Sio Capital Management fully exited AstraZeneca in Q1 2021, selling an estimated $13.1M.
- Sio Capital Management's ten largest holdings make up 38% of its $493M portfolio in Q1 2021.
- Sio Capital Management opened 22 new positions and closed 22 in Q1 2021.
- Sio Capital Management's portfolio value rose 0.85% quarter-over-quarter to $493M.
Based on Sio Capital Management's 13F filing for Q1 2021, filed 14 May 2021.